Titus Wealth Management purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,472 shares of the company’s stock, valued at approximately $211,000.

Several other hedge funds have also modified their holdings of LLY. Franklin Resources Inc. lifted its holdings in shares of Eli Lilly And Co by 14.1% during the first quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock worth $2,517,762,000 after buying an additional 4,022,251 shares during the last quarter. Schroder Investment Management Group increased its position in shares of Eli Lilly And Co by 103.8% during the first quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock valued at $362,806,000 after purchasing an additional 2,388,548 shares during the period. BlackRock Inc. increased its position in shares of Eli Lilly And Co by 3.0% during the first quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock valued at $5,089,436,000 after purchasing an additional 1,926,334 shares during the period. Morgan Stanley increased its position in shares of Eli Lilly And Co by 37.8% during the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after purchasing an additional 1,227,888 shares during the period. Finally, Investec Asset Management LTD increased its position in shares of Eli Lilly And Co by 49.6% during the second quarter. Investec Asset Management LTD now owns 2,528,279 shares of the company’s stock valued at $215,738,000 after purchasing an additional 838,271 shares during the period. Institutional investors own 76.52% of the company’s stock.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 185,000 shares of the company’s stock in a transaction on Tuesday, July 24th. The stock was sold at an average price of $92.03, for a total value of $17,025,550.00. Following the sale, the insider now directly owns 121,631,601 shares in the company, valued at $11,193,756,240.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total value of $63,342.00. Following the completion of the sale, the insider now owns 3,530 shares in the company, valued at $372,662.10. The disclosure for this sale can be found here. Insiders sold 1,685,070 shares of company stock worth $167,108,944 over the last quarter. Company insiders own 0.11% of the company’s stock.

A number of research firms have recently issued reports on LLY. DZ Bank restated a “hold” rating on shares of Eli Lilly And Co in a research report on Friday, June 22nd. Cantor Fitzgerald set a $110.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a research report on Monday. Barclays restated an “overweight” rating and set a $112.00 price objective on shares of Eli Lilly And Co in a research report on Tuesday. Credit Suisse Group set a $84.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a research report on Friday, July 13th. Finally, Jefferies Financial Group set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a research report on Sunday, July 15th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $101.00.

Shares of NYSE:LLY opened at $105.71 on Tuesday. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $107.84. The firm has a market capitalization of $113.60 billion, a price-to-earnings ratio of 24.70, a P/E/G ratio of 1.76 and a beta of 0.27. The company has a current ratio of 1.40, a quick ratio of 1.09 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm had revenue of $6.36 billion for the quarter, compared to analysts’ expectations of $6.05 billion. During the same period in the prior year, the business posted $1.11 earnings per share. The business’s revenue was up 9.1% compared to the same quarter last year. research analysts predict that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.